Review began 04/14/2022 review ended 05/07/2022 published 05/14/2022 © copyright

HIGHLIGHTS

• who: Report et al. from the Clinical Hematology, Mohammed V Military Teaching Hospital, Mohammed V University, Rabat, MAR have published the research: Review began 04/14/2022 Review ended 05/07/2022 Published 05/14/2022 u00a9 Copyright, in the Journal: (JOURNAL) of May/14,/2022
• what: The authors report a case of a 58-year-old woman who presented with PRES after receiving a widely used first-line chemotherapy regimen for B-cell non-Hodgkin lymphomas: the rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin), and prednisone (RCHOP) regimen.
• future: Resumption of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.